A dose escalation followed by dose expansion trial to assess safety and tolerability of CAP-100 in subjects with relapsed/refractory chronic lymphocytic leukemia.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516341-39-00

Acronym

CAP-100-1

Enrollment

Registered

2024-08-27

Start date

2021-08-23

Completion date

Unknown

Last updated

2024-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026